Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Modular Antigen-Specific T-cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins.

Repellin CE, Patel P, Beviglia L, Javitz H, Sambucetti L, Bhatnagar P.

Adv Biosyst. 2018 Dec;2(12). pii: 1800210. doi: 10.1002/adbi.201800210. Epub 2018 Sep 14.

PMID:
30984819
2.

Erratum to "A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore" [Bioorg. Med. Chem. Lett. 27 (2017) 406-412].

Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489. doi: 10.1016/j.bmcl.2017.02.009. Epub 2017 Feb 16. No abstract available.

PMID:
28214076
3.

A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.

Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. doi: 10.1016/j.bmcl.2016.12.056. Epub 2016 Dec 24. Erratum in: Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489.

4.

A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.

Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR.

J Med Chem. 2016 Dec 22;59(24):11161-11170. doi: 10.1021/acs.jmedchem.6b01470. Epub 2016 Dec 12.

5.

Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.

Wang D, Liu X, Hsieh B, Bruce R, Somlo G, Huang J, Sambucetti L.

Arch Med Res. 2015 Nov;46(8):642-50. doi: 10.1016/j.arcmed.2015.11.007. Epub 2015 Dec 1.

6.

A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.

DeMaster LK, Liu X, VanBelzen DJ, Trinité B, Zheng L, Agosto LM, Migueles SA, Connors M, Sambucetti L, Levy DN, Pasternak AO, O'Doherty U.

J Virol. 2015 Nov 4;90(5):2165-79. doi: 10.1128/JVI.01913-15.

7.

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.

Shi Y, Joyner AS, Shadrick W, Palacios G, Lagisetti C, Potter PM, Sambucetti LC, Stamm S, Webb TR.

Pharmacol Res Perspect. 2015 Aug;3(4):e00158. doi: 10.1002/prp2.158. Epub 2015 Jun 26.

8.

5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors.

Laderoute KR, Calaoagan JM, Chao WR, Dinh D, Denko N, Duellman S, Kalra J, Liu X, Papandreou I, Sambucetti L, Boros LG.

J Biol Chem. 2014 Aug 15;289(33):22850-64. doi: 10.1074/jbc.M114.576371. Epub 2014 Jul 3.

9.

SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.

Chao WR, Amin K, Shi Y, Hobbs P, Tanabe M, Tanga M, Jong L, Collins N, Peters R, Laderoute K, Dinh D, Yean D, Hou C, Sato B, Alt C, Sambucetti L.

Angiogenesis. 2011 Mar;14(1):1-16. doi: 10.1007/s10456-010-9191-z. Epub 2010 Nov 21.

PMID:
21104121
10.

A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha).

Duellman SJ, Calaoagan JM, Sato BG, Fine R, Klebansky B, Chao WR, Hobbs P, Collins N, Sambucetti L, Laderoute KR.

Biochem Pharmacol. 2010 Sep 15;80(6):819-26. doi: 10.1016/j.bcp.2010.05.024. Epub 2010 May 31.

11.

The metal-responsive transcription factor-1 protein is elevated in human tumors.

Shi Y, Amin K, Sato BG, Samuelsson SJ, Sambucetti L, Haroon ZA, Laderoute K, Murphy BJ.

Cancer Biol Ther. 2010 Mar 15;9(6):469-76. Epub 2010 Mar 20.

12.

Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.

Xu H, Wang Z, Donaldson JC, Yao H, Zhou S, Kelson AB, Ma W, Weber KT, Laborde E, Cheng M, Sambucetti L, Keck JG.

Anticancer Res. 2009 Oct;29(10):3845-55.

13.

Regulation of IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling pathways.

Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB.

J Inflamm (Lond). 2005 Oct 5;2:10.

14.

Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.

Young JC, Wu S, Hansteen G, Du C, Sambucetti L, Remiszewski S, O'Farrell AM, Hill B, Lavau C, Murray LJ.

Cytotherapy. 2004;6(4):328-36.

PMID:
16146885
15.

NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.

Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB.

J Biol Chem. 2005 Jun 3;280(22):21400-8. Epub 2005 Mar 29.

16.

In vivo bioluminescent monitoring of chemical toxicity using heme oxygenase-luciferase transgenic mice.

Malstrom SE, Jekic-McMullen D, Sambucetti L, Ang A, Reeves R, Purchio AF, Contag PR, West DB.

Toxicol Appl Pharmacol. 2004 Nov 1;200(3):219-28.

PMID:
15504458
17.

PXR and the regulation of apoA1 and HDL-cholesterol in rodents.

Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, Sambucetti L.

Pharmacol Res. 2004 Sep;50(3):237-46.

PMID:
15225665
18.

Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models.

Troy T, Jekic-McMullen D, Sambucetti L, Rice B.

Mol Imaging. 2004 Jan;3(1):9-23.

PMID:
15142408
19.

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S.

Cancer Res. 2004 Jan 15;64(2):689-95.

20.

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P.

J Med Chem. 2003 Oct 9;46(21):4609-24.

PMID:
14521422
21.

Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase.

Piña IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P.

J Org Chem. 2003 May 16;68(10):3866-73.

PMID:
12737565
22.

Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H.

J Med Chem. 2002 Feb 14;45(4):753-7.

PMID:
11831887
23.

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.

Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D.

J Biol Chem. 1999 Dec 3;274(49):34940-7.

24.

Influence of some novel N-substituted azoles and pyridines on rat hepatic CYP3A activity.

Slama JT, Hancock JL, Rho T, Sambucetti L, Bachmann KA.

Biochem Pharmacol. 1998 Jun 1;55(11):1881-92.

PMID:
9714307
25.

Molecular genetic analysis of cytomegalovirus gene regulation in growth, persistence and latency.

Mocarski ES Jr, Abenes GB, Manning WC, Sambucetti LC, Cherrington JM.

Curr Top Microbiol Immunol. 1990;154:47-74. Review. No abstract available.

PMID:
2161325
26.

NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation.

Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES.

EMBO J. 1989 Dec 20;8(13):4251-8.

27.

Common DNA binding site for Fos protein complexes and transcription factor AP-1.

Rauscher FJ 3rd, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM.

Cell. 1988 Feb 12;52(3):471-80.

PMID:
3125983
28.

Analysis of Fos protein complexes and Fos-related antigens by high-resolution two-dimensional gel electrophoresis.

Franza BR Jr, Sambucetti LC, Cohen DR, Curran T.

Oncogene. 1987 May;1(2):213-21.

PMID:
3325882
29.

Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro.

Curran T, Gordon MB, Rubino KL, Sambucetti LC.

Oncogene. 1987;2(1):79-84.

PMID:
3325886
30.

The Fos protein complex is associated with DNA in isolated nuclei and binds to DNA cellulose.

Sambucetti LC, Curran T.

Science. 1986 Dec 12;234(4782):1417-9.

PMID:
3491427
31.

The fos gene product undergoes extensive post-translational modification in eukaryotic but not in prokaryotic cells.

Sambucetti LC, Schaber M, Kramer R, Crowl R, Curran T.

Gene. 1986;43(1-2):69-77.

PMID:
3019839
32.

Synthesis of outer membrane proteins in cpxA cpxB mutants of Escherichia coli K-12.

McEwen J, Sambucetti L, Silverman PM.

J Bacteriol. 1983 Apr;154(1):375-82.

34.

Cellular control of conjugation in Escherichia coli K12. Effect of chromosomal cpx mutations on F-plasmid gene expression.

Sambucetti L, Eoyang L, Silverman PM.

J Mol Biol. 1982 Oct 15;161(1):13-31. No abstract available.

PMID:
6185685
35.
36.

Spectral characteristics of human leukocytes and their relevance to automated cell identification. II. Monocytes.

O'Brien R, Pino I, Sambucetti L, Weeramantry A.

Acta Cytol. 1976 Nov-Dec;20(6):559-64. No abstract available.

PMID:
63206

Supplemental Content

Loading ...
Support Center